7 Giugno 2026

cervantes

Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26 intestino microbiota batteri

Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26

Redazione 2 Giugno 2026
Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase...
Per saperne di più Maggiori informazioni su Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26